LILAC-TIMI 76 Trial Evaluates Factor XI Inhibitor for Atrial Fibrillation Patients
Key Insights
The LILAC-TIMI 76 trial is assessing a novel Factor XI (search) inhibitor as a monthly medication for atrial fibrillation (search) patients at increased risk of stroke (search).
The trial focuses on patients over 65 who are not suitable for current anticoagulants, aiming to reduce bleeding risk while preventing blood clots (search).
Participants will undergo screening and be monitored for approximately 18 months to evaluate the safety and efficacy of the new anticoagulant (search).
A new clinical trial, LILAC-TIMI 76, is underway to evaluate a Factor XI (search) inhibitor as a potential anticoagulant (search) for patients with atrial fibrillation (search) (Afib) who are not currently taking blood thinners. The study aims to determine if this novel approach can effectively prevent stroke (search) with a lower risk of bleeding compared to existing anticoagulants.
Atrial fibrillation (search) increases the risk of stroke (search) because it can cause blood to pool in the heart and form clots. These clots can then travel to the brain, blocking blood flow and causing a stroke. Traditional anticoagulants are often prescribed to reduce this risk, but they can also increase the risk of bleeding.
The LILAC-TIMI 76 trial is recruiting Afib patients aged 65 years or older who, as determined by their doctor, are not appropriate candidates for currently available blood thinners. Eligible participants include those who have never taken a blood thinner or stopped taking one more than 60 days prior to enrollment.
Factor XI Inhibitors: A New Approach
Factor XI (search) inhibitors represent a new class of anticoagulants designed to minimize bleeding complications while still providing protection against harmful blood clots (search). The trial medication is administered monthly.
Participants will undergo an initial screening period involving tests, assessments, and questionnaires to determine their suitability for the trial. The trial duration is expected to be approximately 18 months per participant.
This research offers hope for Afib patients who cannot tolerate current blood thinners, potentially providing a safer and more effective way to prevent stroke (search).